The Pharmacy Times® Migraine Resource Center is a comprehensive resource for clinical news and expert insights on treatments for migraine headaches, which can cause severe throbbing pain or a pulsing sensation.
August 6th 2025
The FDA approved fremanezumab for pediatric migraine prevention, offering a new treatment option for children and adolescents aged 6 to 17 years.
Prevention, Treatment for Migraine Rapidly Evolves, Calling for Development of Novel Drugs
November 21st 2023Zavegepant (Zavzpret; Pfizer) is the first and only only CGRP receptor antagonist as a nasal spray for the acute treatment of migraine in adults with and without aura approved by the FDA.
Read More
Galcanezumab-gnlm Demonstrates Clinically Meaningful Efficacy, Safety in 3 Months for Migraine
June 30th 2023Galcanezumab-gnlm (Emgality; Eli Lilly and Company) did not demonstrate superiority to rimegepant orally disintegrating tablet (Nurtec ODT) on the percentage of individuals achieving a 50% or greater reduction in monthly migraine headache days.
Read More